EUVIMEDEUVIMED entdecken
Open Access

Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort

Rachel E Christensen, Robert Stuver, Stephen Dusza, Zachary D Epstein-Peterson, Paola Ghione, Steven M Horwitz, William Johnson, Alison J Moskowitz, Patricia Myskowski, Melissa Pulitzer, Shamir Geller

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.08.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Rachel E Christensen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Sezary Syndrome, Mycosis Fungoides, Antibodies, Monoclonal, Humanized, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, NIH National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mogamulizumab is more effective in treating the blood component of mycosis fungoides (MF) and Sezary syndrome (SS), though some patients also experience significant skin improvement. The characteristics distinguishing those with a favorable skin response remain unclear. OBJECTIVES: This study aimed to characterize MF/SS patients achieving skin response on mogamulizumab. METHODS: A retrospective chart review at a single cancer center included adult MF/SS patients who received at least one mogamulizumab cycle with follow-up. Skin response (≥ 50% clearance) and blood response (≥ 50% decrease in neoplastic cells/µL) were assessed alongside demographics, disease staging, and prior therapies. RESULTS: Among 56 patients (MF = 35; SS = 21), 43% achieved skin response, with a median time of 2.3 months (range 0.5-6.4). Blood response occurred in 90%, with a median time of 1.8 months (range 0.2-23). Skin-response was highest in patients with blood response (64%), blood disease (B2, 61%), and SS (57%) and was significantly associated with decreasing circulating Sezary cells (P < .001). Among patients without blood involvement (B0), 24% achieved skin response, primarily in erythrodermic cases (71% versus 11%, P = .01). CONCLUSIONS: Mogamulizumab appears effective in inducing skin responses, particularly in advanced-stage and high blood-stage disease. Even in patients without blood compartment involvement, mogamulizumab therapy may still be beneficial, especially for patients with erythroderma. Skin responses are less common in early-stage MF. Patients with both advanced blood and skin disease may benefit from initiating mogamulizumab simultaneously with skin-directed therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sezary SyndromeMycosis FungoidesAntibodies, Monoclonal, HumanizedSkin NeoplasmsSkinHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

CCR4Cutaneous T Cell LymphomaEfficacyImmunotherapyMonoclonal antibody

Substanzen

Antibodies, Monoclonal, Humanizedmogamulizumab

Autor:innen und Institutionen

  • Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: gellers@mskcc.org.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • NIH National Cancer Institute

Zitieren

APA

Christensen, R. E., Stuver, R., Dusza, S., Epstein-Peterson, Z. D., Ghione, P., Horwitz, S. M., Johnson, W., Moskowitz, A. J., Myskowski, P., Pulitzer, M., & Geller, S. (2025). Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.08.008

Vancouver

Christensen RE, Stuver R, Dusza S, Epstein-Peterson ZD, Ghione P, Horwitz SM, et al. Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.08.008

BibTeX
@article{Christensen2025,
  author = {Christensen, Rachel E and Stuver, Robert and Dusza, Stephen and Epstein-Peterson, Zachary D and Ghione, Paola and Horwitz, Steven M and Johnson, William and Moskowitz, Alison J and Myskowski, Patricia and Pulitzer, Melissa and Geller, Shamir},
  title = {Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.08.008}
}
Kostenlos starten →